Vimarsana
Biggest News Aggregation in the World

Page 5 - Amy Wolf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Amy Wolf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Amy Wolf Today - Breaking & Trending Today

Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome - Vimarsana News

Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome

Positive opinion from Committee for Medicinal Products for Human Use based on Bylvay Phase III ASSERT clinical-trial data in Alagille syndrome Negative opinion from Committee for Orphan Medicinal...

Ipsen announces European Commission decision on palovarotene for the treatment of FOP - Vimarsana News

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva Decision follows negative opinion by the Committee for Medicinal...

Ipsen announces European Commission decision on - Vimarsana News

Ipsen announces European Commission decision on

European Commission determines not to grant marketing authorization approval for palovarotene for fibrodysplasia ossificans progressiva (FOP)Decision...

Pottstown grappling with street trash problem - Vimarsana News

Pottstown grappling with street trash problem

It seems unlikely that the people of the borough generate any more trash than people in other towns. What's different is how much more of that trash ends up on the street here.

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Vimarsana News

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo Elafibranor was well tolerated with a safety profile consistent with previous studies Resu...